Skip to main content
Christopher da Costa, MD, Infectious Disease, Furlong, PA

ChristopherThomasda CostaMDPhD, MBA, FACP, FIDSA, CWSP, CPE

Infectious Disease Furlong, PA

Healthcare Associated Infections, International Health, Travel & Tropical, Microbiology, Mycobacterial Disease

Physician-scientist, Immunologist, Internal Medicine, infectious Diseases, Wound Care, Hyperbaric Medicine, Vaccine development, Therapeutic and Immunoprophylactic drug development

Dr. da Costa is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. da Costa's full profile

Already have an account?


  • US licensed and board-certified physician with over 20 years' experience in clinical medicine and over 15 years total of clinical and basic science research experience, including phase I-IV clinical development, medical affairs, health economics & outcomes research, regulatory affairs, and strategic leadership of clinical development teams. Expertise spans vaccine and small molecule clinical research and development, including efficacy, safety, and effectiveness studies for prophylactic pediatric vaccines, as well as expertise in strategic development planning in therapeutic vaccinology, including monoclonal antibody-based active and passive immunotherapy. Therapeutic area experience includes vaccines, infectious diseases, neuroscience, hematology, organ transplantation, and immunology. Clinical experience includes internal medicine, infectious diseases, wound care/ esthetic and hyperbaric medicine. Fellow American College of Physicians, Fellow Infectious Disease Society of America. Certified Wound Specialist Physician.

Education & Training

  • Wharton School, University of PennsylvaniaEntrepreneurial Acceleration Program, Executive education (Business), 2019 - 2019
  • Auburn University MBA, Physician's Executive MBA, 2001 - 2003
  • University Medical Center Southern NevadaChief Residency, Internal Medicine, 1998 - 1999
  • University Medical Center Southern NevadaResidency, Internal Medicine, 1996 - 1998
  • London School of Hygiene & Tropical Medicine PhD, Immunology (Infectious Diseases), 1987 - 1991
  • London School of Hygiene & Tropical Medicine MSc., Clinical Tropical Medicine, 1985 - 1986
  • University of Zambia, School of MedClass of 1983

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2018 - 2022
  • CA State Medical License
    CA State Medical License 2011 - 2014
  • NC State Medical License
    NC State Medical License 2011 - 2016
  • PA State Medical License
    PA State Medical License 2007 - 2022
  • VA State Medical License
    VA State Medical License 2000 - 2016
  • American Board of Internal Medicine Internal Medicine
  • AAPLCertification in Medical Management (CPE)
  • American Board of Wound ManagementCertified Wound Specialist Physician

Awards, Honors, & Recognition

  • Fellow American College of Physicians
  • Fellow Infectious Disease Society of America
  • Best Internal Medicine Resident, Ambulatory Clinic University of Nevada School of Medicine, 1998-1999
  • Join now to see all

Clinical Trials

Publications & Presentations


Journal Articles

  • SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study  
    John Kokai-Kun, PhD, Tracey Roberts, BSN, Olivia Coughlin, PhD, Heidi Whalen, MHS, Charles Le, PhD, Christopher Da Costa, MD, PhD and Joseph Sliman, MD, PhD, Open Forum Infect Dis. 2017 Fall; 4(Suppl 1): S12. Published online 2017 Oct 4. doi: 10.1093/ofid/ofx162.029 PMCID: PMC5631845, 2017
  • Anti-C3d neoantigen-based immune complex ELISA assays for diagnostic and immunopathogenetic investigation of HIV-associated tuberculosis  
    da Costa, C,, 9/1/1994

Books/Book Chapters


  • Immunogenicity of GlaxoSmithKline Biologicals, MMR Vaccine vs M-M-R® II, when Co-administered with Hepatitis A, Varicella and Pneumococcal Conjugate Vaccines to Toddle...
    da Costa, C,, 10/21/2011
  • Efficacy of Two-dose MMRV and One-dose Varicella Vaccination in Children Aged 12-22 Months in 10 European Countries
    da Costa, C,, 5/4/2010
  • Immunogenicity of one dose of Varicella vaccine and two doses of MMRV vaccine.
    da Costa, C,, 5/4/2010
  • Join now to see all


  • Urosepsis 
    Asahi Kasei Pharma America boot camp, French Lick, IN - 10/2015
  • Safety of Recombinant Thrombomodulin 
    Asahi Kasei Pharma America boot camp, French Lick, IN - 10/2015
  • Recombinant Soluble Thrombomodulin in Severe Sepsis with Coagulopathy: Case studies. Investigator Meeting. Asahi Kasei Pharma America. 
    Chicago, IL - 10/2015
  • Join now to see all


Press Mentions

  • Mentoring the Future of Health: An Evening with Dr. Chris Da Costa & Dr. Monica Soni
    Mentoring the Future of Health: An Evening with Dr. Chris Da Costa & Dr. Monica SoniOctober 18th, 2016
  • COVID-19 Alumni Stories: Christopher da Costa
    COVID-19 Alumni Stories: Christopher da CostaJuly 19th, 2020

Grant Support

  • Research Initiative Fund GrantUniversity of Wales College of Medicine1993–1995
  • Beit Memorial Medical Research Fellowship GrantBeit Trust1987–1991

Research History

  • Consultant, Vedanta BiosciencesMIcrobiome Therapeutics for the prevention of recurrent Clostridium difficile Infection, using Bacterial Consortia2018 - Present
  • Vice President of Clinical Development, Synthetic BiologicsClinical research and development of a first-in-class agent for the prevention of Clostridium difficile infection, and of a novel therapy for Irritable Bowel Syndrome with constipation (IBS-C).2017 - Present
  • Physician Reviewer (Consultant)Physician Reviewer for FDA Biologics Safety and Effectiveness Program for Vaccine and Blood Transfusion Products2019 - 2020
  • Consultant, Intarcia Therapeutics, Boston, MAClinical Development and Pharmacovigilance for a Drug-Device combination product for use in Glycemic Control in Diabetes Mellitus.2018 - 2019
  • Global Medical Director, Asahi Kasei Pharma AmericaClinical development of recombinant thrombomodulin as a novel therapy for patients with sepsis, and for the prevention of early allograft dysfunction in liver transplant patients.2015 - 2017
  • Director of Clinical Development, Tuberculosis Vaccines, AerasClinical research and development of TB vaccines.2014 - 2015
  • Senior Medical Director, Pfizer Infectious DiseasesPhase IV clinical research on antibiotics Vancomycin and Linezolid.2011 - 2013
  • Compound Development Team Leader, Janssen Alzheimer Immunotherapy R&D, LLCClinical research on active and passive Immunotherapy for Alzheimer's disease.2010 - 2011
  • Director, Clinical Development and Medical Affairs, GlaxoSmithKline VaccinesClinical research and development of MMR and Varicella vaccines.2006 - 2010
  • Associate Director, Worldwide Regulatory Affairs, Merck and Co.Clinical research on Measles, Mumps, Rubella and Varicella vaccines.2005 - 2006
  • Clinical Lecturer and Research Fellow in Tropical MedicineResearch on immunology of tuberculosis in the context of HIV infection, at the London School of Hygiene & Tropical Medicine.1987 - 1991

Professional Memberships

Other Languages

  • French, Creole